Last updated: October 25, 2026
Humatrope, Eli Lilly’s recombinant human growth hormone, remains a marketed somatropin product but operates in a mature and increasingly competitive market. Its commercial position is supported by long clinical use, physician familiarity, and established pediatric endocrinology distribution. Growth is constrained by multiple somatropin competitors, newer long-acting growth hormone products, payer controls, and the absence of separately reported brand revenue from Eli Lilly.
Humatrope’s financial trajectory cannot be calculated from Eli Lilly’s public filings because the company does not disclose Humatrope revenue, gross margin, prescription volume, or operating profit as a standalone line item. The available evidence supports a mature-product assessment rather than a high-growth asset thesis.
What is Humatrope and how is it used?
Humatrope is recombinant human somatropin, a 191-amino-acid growth hormone produced using recombinant DNA technology. Eli Lilly markets it for selected pediatric and adult growth hormone disorders.
| Attribute |
Humatrope |
| Active ingredient |
Somatropin |
| Sponsor |
Eli Lilly and Company |
| Therapeutic class |
Recombinant human growth hormone |
| FDA regulatory pathway |
Biologics license |
| Primary uses |
Pediatric growth hormone deficiency, idiopathic short stature, selected growth disorders, adult growth hormone deficiency |
| Dosage forms |
Injectable cartridges and vials, depending on market and presentation |
| Administration |
Subcutaneous injection |
| Reference-product class |
Recombinant somatropin |
| Main commercial channel |
Specialty pharmacy, endocrinology, and payer-managed distribution |
FDA labeling restricts use to specified diagnoses and includes contraindications related to active malignancy, acute critical illness, severe obesity associated with respiratory impairment, and other clinically significant conditions. Pediatric treatment generally requires long-term administration and monitoring of growth response, glucose metabolism, thyroid function, intracranial pressure, and orthopedic complications.[1]
Humatrope is not interchangeable across all delivery systems merely because competing products contain somatropin. Device compatibility, cartridge format, injection systems, dosing conventions, storage requirements, and payer formulary status affect treatment selection.
When did Humatrope receive FDA approval?
Humatrope was among the first recombinant human growth hormone products approved in the United States. FDA approval dates differ by indication and supplemental labeling.
| Milestone |
Regulatory significance |
| 1980s |
Recombinant somatropin development and first U.S. approvals |
| 1987 |
Humatrope received U.S. approval for pediatric growth hormone deficiency |
| 2003 |
FDA approved Humatrope for selected children with idiopathic short stature |
| Subsequent years |
Supplemental labeling covered additional pediatric and adult growth hormone deficiency uses |
The idiopathic short stature indication materially expanded the addressable population beyond children with confirmed growth hormone deficiency. That indication also increased payer scrutiny because treatment involves a clinical growth objective rather than correction of a clearly documented hormone deficiency.[1]
What patents protect Humatrope?
Humatrope’s core composition and manufacturing patents are old relative to the product’s market life. The principal commercial protection today is unlikely to come from an unexpired foundational molecule patent. The relevant barriers are regulatory, manufacturing, device, know-how, supply-chain, and payer-related.
Publicly accessible product information does not establish a currently dominant, brand-specific patent estate that would provide Humatrope with modern small-molecule-style exclusivity. Biologic protection is also structured differently from the Orange Book system used for conventional pharmaceuticals.
Does Humatrope have Orange Book patents?
Humatrope is a biologic, not a conventional small-molecule drug. The FDA Orange Book is not the principal listing system for biologic reference products. Biologic reference-product information and approved biosimilar information are generally associated with the FDA Purple Book and the relevant biologics license records.[2]
As a result:
- Humatrope should not be analyzed through an ordinary Orange Book patent-expiration framework.
- Patent disputes involving a proposed biosimilar follow the Biologics Price Competition and Innovation Act, including the statutory information-exchange process commonly called the "patent dance."
- Patent listings, licensing rights, manufacturing patents, and device rights may be spread across different owners and databases.
- The absence of an Orange Book listing does not mean the product has no potentially relevant patent rights.
What is Humatrope’s regulatory exclusivity position?
Humatrope has been marketed for decades. It is therefore beyond the practical life of the 12-year reference-product exclusivity period created under the Biologics Price Competition and Innovation Act. Any current competitive protection must come from patents, manufacturing complexity, regulatory barriers, contractual arrangements, or commercial execution rather than unexpired reference-product exclusivity.[3]
Which companies compete with Humatrope?
Humatrope competes in a broad somatropin market rather than against one substitute product. Major branded competitors include Pfizer’s Genotropin, Novo Nordisk’s Norditropin, Merck KGaA’s Saizen, and Ascendis Pharma’s Skytrofa. Sogroya, also from Novo Nordisk, competes as a once-weekly growth hormone product rather than as a traditional daily somatropin presentation.
| Product |
Company |
Active ingredient or platform |
Dosing positioning |
| Humatrope |
Eli Lilly |
Somatropin |
Traditional recombinant growth hormone |
| Genotropin |
Pfizer |
Somatropin |
Traditional recombinant growth hormone |
| Norditropin |
Novo Nordisk |
Somatropin |
Traditional recombinant growth hormone |
| Saizen |
Merck KGaA |
Somatropin |
Traditional recombinant growth hormone |
| Omnitrope |
Sandoz |
Somatropin |
Biosimilar somatropin in the U.S. |
| Skytrofa |
Ascendis Pharma |
Long-acting growth hormone |
Once-weekly administration |
| Sogroya |
Novo Nordisk |
Long-acting somapacitan |
Once-weekly administration |
Omnitrope is the most direct U.S. biosimilar comparator. FDA approved Omnitrope as a biosimilar to Genotropin, not as a biosimilar to Humatrope.[4] Because somatropin products are highly similar biologically but may differ in approved indications, devices, labeling, and interchangeability status, biosimilar competition can affect Humatrope pricing without requiring a product to reference Humatrope directly.
How strong is the Humatrope patent estate?
Humatrope’s patent estate appears commercially weaker than the patent estates of newer long-acting growth hormone products.
Composition and manufacturing protection
The basic recombinant somatropin technology was developed and patented decades ago. Core composition claims would generally have expired or lost practical exclusivity. Manufacturing know-how can remain valuable because recombinant protein production depends on cell lines, fermentation, purification, aggregation control, potency testing, and stability management.
These factors can create entry friction but usually do not block a well-funded biosimilar developer that can establish analytical similarity, manufacturing controls, and clinical or pharmacologic comparability.
Formulation and device protection
The relevant commercial rights may include:
- Stabilized liquid or lyophilized formulations.
- Cartridge and pen delivery systems.
- Dose-setting mechanisms.
- Injection-device components.
- Storage and reconstitution systems.
- Manufacturing processes that improve protein stability or reduce aggregation.
Device and formulation rights can influence litigation strategy, but they do not necessarily prevent a competing somatropin product using a different presentation.
Method-of-use patents
Method-of-use patents may cover treatment of pediatric growth hormone deficiency, idiopathic short stature, adult growth hormone deficiency, or dosing approaches. Their commercial value is limited by:
- The breadth of the claims.
- Physician prescribing practices.
- Labeling of competing products.
- Inducement and contributory-infringement theories.
- The ability of a biosimilar applicant to omit patented indications through a "skinny label."
Humatrope therefore has no clear modern patent barrier equivalent to a late-life formulation or delivery patent portfolio supporting a protected small-molecule franchise.
When does Humatrope lose exclusivity?
Humatrope’s principal product exclusivity was lost long ago. The relevant current question is when competitors can capture volume and pricing, not when a single foundational patent expires.
Exclusivity timeline
| Period |
Commercial position |
| 1987 onward |
Established recombinant somatropin product |
| 2003 |
Expanded use through idiopathic short stature approval |
| 2000s and 2010s |
Increasing competition from Genotropin, Norditropin, Saizen, and Omnitrope |
| 2010s onward |
Biosimilar and payer pressure increased |
| 2021 onward |
Long-acting growth hormone products introduced additional adherence competition |
| Current market |
Mature branded product with regulatory and manufacturing barriers but limited foundational exclusivity |
Humatrope does not appear to have a meaningful remaining FDA reference-product exclusivity period. Product risk is driven by formulary displacement, biosimilar adoption, long-acting alternatives, and possible manufacturing or supply constraints.
What is the Humatrope Orange Book and Purple Book status?
Humatrope should be evaluated through its biologics license and FDA biologics records rather than through a conventional Orange Book patent table. The Purple Book identifies licensed biological products and biosimilar relationships, but it is not a complete patent-clearance report.
Omnitrope’s biosimilar approval establishes that the FDA has accepted a somatropin biosimilar pathway for the class. It does not automatically create an FDA interchangeability designation for Humatrope. Interchangeability depends on the specific reference product, application, and FDA determination.[2][4]
Which companies are challenging Humatrope?
No single high-profile Paragraph IV campaign defines Humatrope’s current market position. Paragraph IV litigation is primarily associated with abbreviated new drug applications for small-molecule products. Biosimilar applicants use a different regulatory and patent process.
The relevant competitive threats are:
- Existing somatropin brands with contracting power.
- Omnitrope and other potential biosimilar entrants.
- Long-acting products that reduce injection frequency.
- Payer-preferred products selected through rebates and specialty-pharmacy agreements.
- Products with integrated injection devices and patient-support programs.
A direct Humatrope biosimilar challenge would likely focus on analytical comparability, clinical pharmacology, manufacturing controls, and any enforceable formulation or device rights. A competitor could also seek approval while omitting a patented indication.
What generic or biosimilar launch risks exist for Humatrope?
The near-term risk is commercial erosion rather than an immediate cliff launch. Somatropin markets have several characteristics that slow rapid substitution:
- Pediatric endocrinologists may prefer products with long clinical experience.
- Patients and caregivers may resist changing injection devices.
- Growth hormone treatment requires ongoing monitoring.
- Specialty pharmacies and wholesalers influence product access.
- Payers often use prior authorization and preferred-product protocols.
- Biosimilar substitution rules vary by product and jurisdiction.
Long-acting growth hormone creates a different risk. A weekly product can compete even without being a Humatrope biosimilar because it changes the adherence and convenience proposition. This can shift prescribing decisions away from daily somatropin products.
How does Humatrope compare with long-acting growth hormone products?
| Factor |
Humatrope |
Weekly growth hormone products |
| Dosing frequency |
Typically daily |
Weekly |
| Clinical history |
Long-established |
Newer |
| Switching barrier |
Device and patient familiarity |
New initiation or conversion decision |
| Patent profile |
Mature product technology |
Newer platform and formulation patents |
| Adherence proposition |
More injections |
Fewer injections |
| Payer dynamics |
Contracting and established coverage |
Premium-price justification required |
| Main risk |
Price and formulary erosion |
Patient migration and new-start capture |
Long-acting products may command higher prices but face reimbursement scrutiny. Their adoption depends on demonstrated adherence, outcomes, patient preference, and payer willingness to cover a premium.
What is Humatrope’s financial trajectory?
Eli Lilly does not publicly report Humatrope as a separate revenue-generating segment in its annual reports. Humatrope is included within broader product categories, and the company’s recent financial growth has been driven by newer medicines, including incretin products, oncology products, immunology products, and other pipeline launches rather than mature growth hormone revenue.[5]
Financial profile
| Metric |
Publicly disclosed position |
| Standalone Humatrope revenue |
Not separately reported |
| Standalone operating profit |
Not separately reported |
| Brand-level prescription trend |
Not disclosed by Lilly in annual reports |
| Revenue growth profile |
Mature or declining relative to Lilly’s growth franchises |
| Margin exposure |
Likely supported by established manufacturing, but pressured by rebates and specialty distribution |
| Capital requirements |
Lower than for a newly launched biologic, with ongoing quality, supply, and postmarketing costs |
Humatrope likely remains financially useful as a cash-generating specialty product, but it is unlikely to be a material driver of Eli Lilly’s consolidated growth. The economic value of the brand depends on price realization, manufacturing efficiency, payer access, and retention of pediatric and adult endocrinology patients.
What licensing deals affect Humatrope?
No major recent Humatrope-specific licensing transaction is central to the public market narrative. Eli Lilly developed and commercialized Humatrope as its own product. The competitive landscape is shaped more by product ownership, biosimilar development, distribution agreements, and payer contracting than by a disclosed Humatrope asset sale or co-development deal.
Potentially relevant commercial rights can include regional distribution, specialty-pharmacy arrangements, device supply, and manufacturing contracts. These arrangements are generally not disclosed at a brand-specific level in Lilly’s public filings.
What patent litigation affects Humatrope?
There is no widely reported, current litigation campaign that creates a near-term Humatrope exclusivity event comparable to major small-molecule patent litigation. Litigation risk remains possible around:
- Biosimilar patent disputes.
- Manufacturing-process claims.
- Formulation claims.
- Delivery-device patents.
- Trade secrets and confidential know-how.
- Contractual or distribution disputes.
The absence of a major public case does not establish freedom to operate for every competing somatropin product. It indicates that current public market risk is more commercial than litigation-driven.
What geographic markets matter for Humatrope?
The United States remains strategically important because of high biologic pricing, specialty-pharmacy infrastructure, and extensive pediatric endocrinology demand. European markets impose stronger health-technology assessment and price-control pressures. Emerging markets can offer volume but generally produce lower net prices and greater exposure to local registration, reimbursement, and supply-chain requirements.
Geographic value is therefore uneven:
| Region |
Main opportunity |
Main constraint |
| United States |
Higher prices and established specialist market |
Prior authorization, rebates, biosimilar pressure |
| Europe |
Broad regulatory access |
Price controls and tendering |
| Japan |
Established endocrine market |
Reimbursement and regulatory requirements |
| Emerging markets |
Patient-volume expansion |
Lower prices, local competition, distribution complexity |
What manufacturing and intellectual-property barriers protect Humatrope?
Manufacturing remains a meaningful barrier even after core patents expire. A competitor must demonstrate consistent recombinant protein quality, control impurities and aggregates, maintain potency, validate sterile production, and satisfy FDA inspection requirements.
For Humatrope, the strongest practical protections are likely:
- Validated recombinant production processes.
- Product-specific analytical methods.
- Long-term stability data.
- Regulatory history.
- Distribution and specialty-pharmacy relationships.
- Physician and patient familiarity.
- Device and packaging integration.
These protections can preserve a brand franchise but are less durable than a live composition patent.
What is the outlook for Humatrope?
Humatrope’s outlook is stable to pressured. The product has a durable clinical position but limited structural growth. Revenue risk is likely to emerge through gradual share loss, lower net pricing, and payer-led switching rather than through a single patent-expiration event.
The strongest defenses are brand trust, treatment continuity, supply reliability, physician familiarity, and contracting. The largest threats are biosimilar availability, preferred formulary placement for rival somatropin products, weekly growth hormone adoption, and reduced willingness to reimburse treatment for idiopathic short stature.
Key Takeaways
- Humatrope is a mature recombinant somatropin product owned by Eli Lilly.
- Its core product technology is decades old, and modern reference-product exclusivity is no longer relevant.
- Humatrope is a biologic and should be analyzed through FDA biologics and Purple Book frameworks rather than a conventional Orange Book review.
- Omnitrope demonstrates an established U.S. biosimilar pathway for somatropin, although it references Genotropin rather than Humatrope.
- Genotropin, Norditropin, Saizen, Omnitrope, Skytrofa, and Sogroya create both direct and indirect competitive pressure.
- Lilly does not separately report Humatrope revenue, preventing a defensible standalone revenue forecast from public filings.
- The brand’s financial trajectory is likely mature to declining, with value supported by manufacturing capability, clinical familiarity, and specialty distribution.
- The most credible risks are formulary erosion, biosimilar competition, weekly growth hormone substitution, and lower net pricing.
- No current major Humatrope patent litigation campaign publicly defines the market.
FAQs About Humatrope Market and Patent Risk
Is Humatrope still commercially available?
Yes. Humatrope remains an FDA-approved somatropin product marketed by Eli Lilly, subject to product availability, country-specific labeling, and distribution conditions.
Is Omnitrope interchangeable with Humatrope?
Not automatically. Omnitrope was approved as a biosimilar to Genotropin. Interchangeability depends on the specific FDA designation and applicable substitution law, not merely on both products containing somatropin.
Does Humatrope have a patent cliff?
Humatrope has no obvious modern patent cliff comparable to a recently launched small-molecule medicine. Its principal risk is gradual commercial erosion caused by competition, payer controls, and long-acting alternatives.
Which growth hormone has the strongest competitive position?
No single product dominates every segment. Norditropin and Genotropin have extensive commercial histories, Omnitrope has biosimilar positioning, and Skytrofa and Sogroya compete through weekly dosing and newer delivery platforms.
Is Humatrope revenue material to Eli Lilly?
Lilly does not disclose Humatrope revenue separately. Relative to Lilly’s largest current growth products, Humatrope is best assessed as a mature specialty asset rather than a consolidated-company growth driver.
References
-
U.S. Food and Drug Administration. (2023). Humatrope (somatropin) prescribing information. Eli Lilly and Company/FDA labeling database.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
-
U.S. Food and Drug Administration. (2024). Biologics Price Competition and Innovation Act. FDA Biosimilars Guidance and Regulatory Information.
-
U.S. Food and Drug Administration. (2006). Approval package for Omnitrope (somatropin), BLA 125147. FDA Center for Drug Evaluation and Research.
-
Eli Lilly and Company. (2024). 2023 annual report. Indianapolis, IN: Eli Lilly and Company.
